Drug discovery platform using functional antibody selection at 100M-antibody scale to create target-activating drugs for GPCRs.
Abalone Bio's FAST (Functional Antibody Selection Technology) platform measures the functional activity of hundreds of millions of antibodies per experiment using engineered yeast cells that link cell survival to antibody activity against a target — 100x more throughput than others. This generates large proprietary activity datasets that enable machine learning to design activating antibodies for GPCRs, the hardest target class. The company focuses on diseases where inhibition-only approaches have failed and collaborates with top drug companies. Abalone Bio is a product of Abalone Bio.